Stay updated on Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedThe webpage has undergone significant updates, including the addition of a new study on breast cancer involving pembrolizumab and Olaparib, and the identification of collaborators such as Merck Sharp & Dohme LLC. The previous version's detailed trial description and inclusion/exclusion criteria have been removed.SummaryDifference55%
- Check10 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check17 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check53 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check68 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.SummaryDifference1%
- Check75 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check89 days agoChange DetectedThe website has been updated from version v2.14.0 to v2.14.1.SummaryDifference0.1%
Stay in the know with updates to Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Olaparib in BRCA Breast Cancer Clinical Trial page.